NICE’s positive recommendation for Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) applies to adults who have stage III BRAF V600 mutation-positive melanoma that has spread to nearby lymph vessels or lymph glands, which make up an important part of our immune system. Dabrafenib plus trametinib would be given to patients who have already had surgery…